Evidence map›Paper›PMID 24986801›Full record

ArticleBone marrow transplantation2014

Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

L Tucunduva, A Ruggeri, G Sanz, S Furst, G Socié, M Michallet, W Arcese, N Milpied, I Yakoub-Agha, W Linkesch and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
  2. Article
  3. Article
  4. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

L Tucunduva1]  Eurocord AP-HP, University Paris-Diderot, Saint-Louis Hospital , Paris, France [2] Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil.
A Ruggeri1]  Eurocord AP-HP, University Paris-Diderot, Saint-Louis Hospital , Paris, France [2] Rome Transplant Network, University Tor Vergata, Rome, Italy.
G SanzServicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain.
S FurstDepartment of Hematology, Institut Paoli Calmettes, Marseille, France.
G SociéDepartment of Hematology, Bone Marrow Transplantation Unit, Saint-Louis Hospital, Paris, France.
M MichalletDepartment of Hematology, Edouard Herriot Hospital, Lyon, France.
W ArceseDivision of Hematology, Stem Cell Transplant Unit, University of Rome Tor Vergata, Rome, Italy.
N MilpiedDepartment of Hematology, CHU Bordeaux, Hôpital Haut-leveque, Pessac, France.
I Yakoub-AghaDivision of Hematology, CHU de Lille, Lille, France.
W LinkeschDivision of Hematology, Medical University Graz, Graz, Austria.
J CornelissenDepartment of Hematology, Erasmus MC/Daniel Den Hoed, Rotterdam, Netherlands.
L MannoneService d'hématologie clinique, Hôpital de l'ARCHET, Nice, France.
A P IoriDepartment of Cell Biotechnology and Hematology, University La Sapienza, Rome, Italy.
J-M RiberaDepartment of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain.
J SanzServicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain.
P MontesinosServicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain.
D Purtill160;Eurocord AP-HP, University Paris-Diderot, Saint-Louis Hospital , Paris, France.
M LabopinService d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Université Paris 6, UMR-S 938, CEREST-TC EBMT, Hôpital Saint Antoine, Paris, France.
E Gluckman160;Eurocord AP-HP, University Paris-Diderot, Saint-Louis Hospital , Paris, France.
M MohtyService d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Université Paris 6, UMR-S 938, CEREST-TC EBMT, Hôpital Saint Antoine, Paris, France.
V Rocha1]  Eurocord AP-HP, University Paris-Diderot, Saint-Louis Hospital , Paris, France [2] Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil [3] Department of Hematology, Churchill Hospital, Oxford University Hospitals, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We performed a retrospective analysis on 421 adult patients who underwent unrelated cord blood transplantation (UCBT) for ALL. Median age was 32 years; 46% were in first CR (CR1), 32% in CR2 and 22% had advanced disease. Double UCBT was performed in 173 patients (41%). Myeloablative conditioning (MAC) was given to 314 patients (75%). Cumulative incidence (CI) of 60-day neutrophil recovery was 78%. CI of acute and chronic GVHD was 33 and 26%, respectively. Non-relapse mortality (NRM) at 2 years was 42%. Age⩾35 years (P<0.0001), advanced disease at UCBT (P<0.0001) and use of MAC (P<0.0001) were associated with increased NRM. Relapse incidence (RI) at 2 years was 28%; use of reduced intensity conditioning (RIC) (P=0.0002) was associated with increased RI. Two-year leukemia-free survival (LFS) was 39% for patients in CR1, 31% for CR2 and 8% for advanced disease. In multivariate analysis, factors associated with decreased LFS rate were: age ⩾35 years (P=0.034), use of MAC (P=0.032) and advanced disease (P<0.0001). These results show that UCBT is a valuable option to treat high-risk adult ALL when in remission. Strategies to decrease toxicity and relapse are needed to improve final outcomes.

Indexed as

AdolescentAdultAgedCord Blood Stem Cell TransplantationEuropeFemaleGraft vs Host DiseaseHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesRisk FactorsTreatment OutcomeUnrelated DonorsYoung Adult

Identifiers

PMID24986801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.